Key result
Long-term use of low-dose aspirin in patients with cardiovascular disease was not associated with sensorineural hearing loss compared to age-matched controls.
Why the study?
Does long-term low-dose aspirin therapy cause hearing loss or tinnitus in patients with cardiovascular disease?
Cross-Sectional (n=403)
No
Does long-term low-dose aspirin therapy cause hearing loss or tinnitus in patients with cardiovascular disease?
Long-term use of low-dose aspirin for cardiovascular disease is not associated with an increased risk of hearing loss or tinnitus when adjusting for age and comorbidities.
Answers are grounded in this paper and cite their sources.
Reassures on hearing safety of long-term low-dose aspirin; cross-sectional design leaves open need for prospective confirmation.
<ns4:p> <ns4:bold>Introduction</ns4:bold> : Aspirin is a routinely prescribed drug, most notably for cardiovascular diseases, such as myocardial ischemia. This cross sectional, comparative study study aims to explore differences in hearing status between the cardiovascular disease patients on aspirin therapy and age matched controls. </ns4:p> <ns4:p> <ns4:bold>Methods</ns4:bold> : The study population consisted of 182 patients with heart disease taking long term aspirin (i.e., for more than one year). The control population consisted of 221 age matched controls who were not taking aspirin. </ns4:p> <ns4:p> <ns4:bold>Results</ns4:bold> : It was found that age of patient, not aspirin intake, was more important risk factor contributing to hearing loss. </ns4:p> <ns4:p> <ns4:bold>Conclusions</ns4:bold> : When confounding factors like age of the patient, hypertension and diabetes were taken into account, aspirin in its antiplatelet dose was not found to be the cause of any audiological problems like tinnitus and hearing loss. </ns4:p>
No takes yet. Share an insight, caveat, or question.
Pokharel et al. (2018) conducted a cross-sectional in Cardiovascular disease (n=403). Long-term aspirin therapy vs. Age-matched controls not taking aspirin was evaluated on Sensorineural hearing loss (SNHL) (p=0.68). Long-term use of low-dose aspirin in patients with cardiovascular disease was not associated with sensorineural hearing loss compared to age-matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: